NEW YORK – The UK's National Institute for Health and Care Excellence on Thursday issued two final guidances, in which it recommended against making Eisai and Biogen's Leqembi (lecanemab) and Eli ...

NEW YORK – Singapore's Ministry of Health announced this week it will launch a genetic testing program to improve diagnosis of familial hypercholesterolemia (FH) as part of a broader national focus on ...

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

Lyell Immunopharma announced new clinical data Tuesday from a Phase I/II trial of its dual-targeted CD19/CD20 CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. The company ...

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

The decision comes as the company is discontinuing clinical testing of a CLDN6-targeted CAR T-cell therapy in testicular cancer.